AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in ...

AstraZeneca's oncology portfolio continues to deliver, with a recommendation for EU approval of its new Imfinzi/Imjudo immunotherapy combination heading a flurry of regulatory updates. The EMA's ...

AstraZeneca's ASCO 'super sunday' delivers new data for Tagrisso and Imfinzi in lung cancer and Enhertu in breast cancer ...

The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a ...

It came in a box with a bow and a card that read, 'Our present this year is a contribution towards your home.' Three years later he is asking for the money back (plus interest!), referring to it ...

Anchors raking in millions of dollars per year have targets on their backs, thanks to competitors matching and even surpassing their ratings at a fraction of the cost.